GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel

Status Withdrawn

Clinical Trial Summary

Taxane-induced peripheral neuropathy (TIPN) caused by albumin-bound paclitaxel is a dose-limiting toxicity. The main symptoms of discomfort are numbness, tingling, and burning sensations in the glove-sock-like distribution of the limbs. At present, there are few effective methods for clinical treatment of TIPN, and there is no widely agreed consensus on effective treatment in the world. Therefore, it is of great clinical significance and practical value to carry out clinical research to explore drugs to relieve TIPN.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04538833
Study type	Interventional
Source	Henan Cancer Hospital
Contact
Status	Withdrawn
Phase	Phase 2
Start date	September 9, 2020
Completion date	August 22, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04436744` - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)	Phase 2
Completed	`NCT02187744` - A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)	Phase 3
Terminated	`NCT01155063` - Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients	N/A
Recruiting	`NCT03949634` - Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)	Phase 3
Active, not recruiting	`NCT05730647` - Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients
Terminated	`NCT01919229` - A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)	Phase 2
Active, not recruiting	`NCT04293393` - Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients	Phase 2
Completed	`NCT00713141` - Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer	N/A
Recruiting	`NCT06341894` - Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer	Phase 2
Recruiting	`NCT03520894` - Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer	N/A
Completed	`NCT03786198` - Activity Program During Aromatase Inhibitor Therapy	N/A
Completed	`NCT01613352` - Feasibility of Ambulatory Surgery for Early Breast Cancer	N/A
Completed	`NCT02738970` - A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)	Phase 1
Recruiting	`NCT01792726` - A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.	N/A
Completed	`NCT00323479` - Arthralgia During Anastrozole Therapy for Breast Cancer	Phase 4
Completed	`NCT03493854` - A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer	Phase 3
Recruiting	`NCT04291378` - The DBCG Proton Trial: Photon Versus Proton Radiation Therapy for Early Breast Cancer	N/A
Active, not recruiting	`NCT05415215` - A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer	Phase 3
Not yet recruiting	`NCT06371807` - Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab	Phase 2
Not yet recruiting	`NCT04659499` - Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer	Phase 2